이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Capillary Sampling in Clinical Populations Undergoing Monitoring (CAPSICUM)

2026년 8월 28일 업데이트: University of Edinburgh

Many people with long-term health conditions require regular blood tests to monitor their disease or medications. These blood tests are usually performed by taking blood from a vein during a hospital or clinic appointment. This can be inconvenient, time-consuming and difficult for some people, particularly those who live far from hospital, have reduced mobility, require frequent tests, or experience anxiety about attending healthcare settings or having blood taken.

Capillary blood sampling devices allow people to collect a small blood sample themselves, usually from the upper arm or fingertip, which can then be sent to a laboratory by post. These devices have shown promising results for some blood tests, but there is insufficient evidence of which tests remain accurate when samples are collected at home, posted to the laboratory and subjected to postage conditions and delayed analysis.

The CAPSICUM study will compare blood samples collected using patient-operated capillary sampling devices with routine venous blood samples already being taken as part of participants' usual clinical care. We will investigate whether a wide range of blood tests produce similar results using both methods and assess how delayed analysis, postal transport and home collection affect test accuracy.

Participants will attend only one study visit, which will take place during a routine clinic appointment. Some participants will also be invited to collect an additional blood sample at home and return it by post, and to complete a brief questionnaire about their experience.

The findings from this study will help identify which blood tests can be safely monitored using home capillary blood sampling. This could improve access to blood monitoring, reduce unnecessary hospital visits, make monitoring more convenient for patients, and support the development of safe, evidence-based remote monitoring pathways within the NHS.

연구 개요

연구 유형

관찰

등록 (추정된)

1000

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Richard Shemilt, MBChB
  • 전화번호: +441312427978
  • 이메일: rshemilt@ed.ac.uk

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

A maximum of 1000 participants will be recruited. The study aims to include approximately 200 participants from each of five clinical populations in which regular blood monitoring forms part of routine care and where remote capillary blood sampling has the potential to improve access to monitoring or patient experience:

  • Patients with kidney disease
  • Patients with immune-mediated disease
  • Kidney, kidney-pancreas and islet transplant recipients
  • Patients with mental health disorders requiring regular blood monitoring
  • Children attending paediatric services who require regular blood monitoring

설명

Inclusion Criteria:

Eligible participants are individuals who require routine venous blood sampling as part of their usual clinical care and who represent clinical populations in which remote capillary blood sampling may improve access to monitoring or patient experience.

All participants must:

  • Be attending a routine clinical appointment during which venous blood sampling is planned as part of standard clinical care for disease monitoring or therapeutic drug monitoring.
  • Be willing and able to undertake capillary blood sampling independently or with appropriate assistance.

Adult participants must:

  • Be aged ≥18 years of age.
  • Have capacity to provide written informed consent.

Paediatric participants must:

  • Be aged 6-15 years of age.
  • If aged 6-11, be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable.
  • If aged 12-15: be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable OR if deemed to have capacity themselves, be able to provide written informed consent and be attending with a parent or legal guardian who agrees to their participation.

Additional eligibility criteria

Autoimmune disease group: participants must have a diagnosis of immune-mediated disease based on the assessment of their treating clinician.

Transplant recipient group: participants must be the recipient of a functioning kidney, kidney-pancreas, or islet transplant.

Mental health group: participants must have a diagnosis of a mental health disorder based on the assessment of their treating clinician.

Paediatric group: participants must be attending a paediatric clinic and require blood sampling as part of standard clinical care.

Exclusion Criteria:

  • Inability or unwillingness to provide informed consent, or, for paediatric participants, absence of parental or legal guardian consent or age-appropriate assent where applicable.
  • Skin disease, infection, injury, or other local factors at the intended sampling site that would make capillary blood collection unsafe or impractical.
  • Known allergy or hypersensitivity to any materials used in the capillary blood sampling devices.
  • Inability to undertake the capillary sampling procedures independently or with appropriate assistance.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Patients with kidney disease
Blood sampling with capillary sampling device(s)
Patients with immune-mediated disease
e.g. ANCA-associated vasculitis or systemic lupus erythematosus
Blood sampling with capillary sampling device(s)
Kidney, kidney-pancreas and islet transplant recipients
Blood sampling with capillary sampling device(s)
Patients with mental health disorders who experience barriers to conventional blood sampling
Blood sampling with capillary sampling device(s)
Children requiring regular blood monitoring
Blood sampling with capillary sampling device(s)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
For each pre-defined analyte, the mean difference and 95% limits of agreement between paired capillary and venous blood sample results under immediate analysis conditions, assessed against predefined clinically acceptable limits of agreement.
기간: From enrollment to end of study visit 1
From enrollment to end of study visit 1

2차 결과 측정

결과 측정
기간
Mean difference and 95% limits of agreement following delayed analysis (24-48 hours).
기간: From enrollment to end of study visit 1
From enrollment to end of study visit 1
Mean difference and 95% limits of agreement following delayed analysis after exposure to temperatures representative of routine postal transport.
기간: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Mean difference and 95% limits of agreement following unsupervised patient-led home collection and postal return.
기간: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Proportion of successful capillary sample collections and proportion of samples unsuitable for laboratory analysis, by analyte, patient group and sampling device.
기간: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Reasons for unsuccessful sample collection or laboratory rejection, where available
기간: Enrollment to end of study visit 1
Enrollment to end of study visit 1
Participant acceptability, pain, ease of use and overall preference for capillary sampling compared with venepuncture, assessed using validated questionnaires.
기간: Enrollment to end of study visit 1
Enrollment to end of study visit 1

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 1일

기본 완료 (추정된)

2029년 9월 30일

연구 완료 (추정된)

2029년 9월 30일

연구 등록 날짜

최초 제출

2026년 8월 28일

QC 기준을 충족하는 최초 제출

2026년 8월 28일

처음 게시됨 (실제)

2026년 9월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 28일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다